Polo-like Kinase (PLK)

(PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Comparison

Polo-like Kinase (PLK) Related Products (88)
Recombinant Proteins (2)
Antibodies (3)
Polo-like Kinase (PLK) Isoform Comparison

By Effects:	Inhibitors (84) Degrader (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-102069

3MB-PP1	Inhibitor	99.66%
3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC₅₀=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.

HY-12300B

Ocifisertib fumarate	Inhibitor	99.44%
CFI-400945 fumarate is a potent, selective and orally bioavailable PLK4 inhibitor with a K_i and an IC₅₀ of 0.26 nM and 2.8 nM, respectively.

HY-12045

HMN-214	Inhibitor	99.16%
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

HY-108597

TC-S 7005	Inhibitor	99.68%
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively.

HY-147298

Plogosertib	Inhibitor	99.95%
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC₅₀: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers.

HY-12134

Poloxin	Inhibitor	98.01%
Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC₅₀ of appr 4.8 μM.

HY-15158

SBE13 Hydrochloride	Inhibitor	99.66%
SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-132135

(1E)-CFI-400437 dihydrochloride	Inhibitor	98.08%
(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, VEGFR2/KDR/Flk-1 and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity.

HY-123467

Lasiokaurin	Inhibitor	99.68%
Lasiokaurin is a diterpenoid compound isolated from Isodon lasiocarpus.

HY-13994

Mps1-IN-2	Inhibitor	98.04%
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC₅₀ and a K_d of 145 nM and 12 nM for Mps1 and a K_d of 61 nM for Plk1.

HY-151971

Aurora kinase-IN-3	Inhibitor	98.47%
Aurora kinase-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10.

HY-159493

BI2536-PEG2-Halo	Inhibitor	99.44%
BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC₅₀=23 nM), exhibits selective toxicity against p53 mutant cancer cells.

HY-N8692

Dihydrobaicalein	Inhibitor	99.94%
Dihydrobaicalein is a PLK1 Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens.

HY-128493

PLK4-IN-4	Inhibitor	99.89%
PLK4-IN-4 (compound 22) is a potent PLK4 inhibitor with an IC₅₀ value of 7.9 nM. PLK4-IN-4 has the potential for the research of cancer.

HY-13647

HMN-176	Inhibitor	98.84%
HMN-176?is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.?

HY-15159

Cyclapolin 9	Inhibitor	99.16%
Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 500 nM. Cyclapolin 9 is inactive against other kinases.

HY-149324

SP27	Degrader	99.21%
SP27 is a PROTAC that can selective degrades PLK4, with a DC₅₀ of 19.5 nM. SP27 can be used for the research of breast cancer.

HY-158031

PLK1/BRD4-IN-5	Inhibitor	99.55%
PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC₅₀ values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research.

HY-117291A

XMD-17-51 TFA		99.46%
XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases.

HY-126249

AAPK-25	Inhibitor	98.31%
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM.

Wortmannin			PLK3, IC₅₀: 48 nM		99.86%
Volasertib	PLK1, IC₅₀: 0.87 nM	PLK2, IC₅₀: 5 nM	PLK3, IC₅₀: 56 nM		99.87%
BI 2536	PLK1, IC₅₀: 0.83 nM	Plk2/Snk, IC₅₀: 3.5 nM	Plk3/Fnk, IC₅₀: 9 nM		99.95%
Onvansertib	PLK1, IC₅₀: 2 nM				99.55%
Centrinone				PLK4, Ki: 0.16 nM PLK4 (G95L), Ki: 68.57 nM	98.28%
RP-1664				PLK4
PLK1-IN-11	PLK1, IC₅₀: 1 μM
GSK461364	PLK1, Ki: 2.2 nM				99.82%
ON1231320	PLK1, IC₅₀: >10 μM	PLK2, IC₅₀: 0.31 μM	PLK3, IC₅₀: >10 μM	PLK4, IC₅₀: >10 μM	99.24%
Rigosertib	PLK1, IC₅₀: 9 nM	PLK2, IC₅₀: 260 nM			99.01%
Centrinone-B				PLK4, Ki: 0.59 nM PLK4 (G95L), Ki: 497.53 nM	98.46%
Ocifisertib				PLK4, IC₅₀: 2.8 nM	99.78%
Rigosertib sodium	PLK1, IC₅₀: 9 nM	PLK2, IC₅₀: 260 nM			99.57%
GW843682X	PLK1, IC₅₀: 2.2 nM		PLK3, IC₅₀: 9.1 nM		99.89%
MLN0905	PLK1, IC₅₀: 2 nM				99.94%
Ro3280	PLK1, Kd: 0.09 nM				98.87%
TAK-960	PLK1, IC₅₀: 0.8 nM	PLK2, IC₅₀: 16.9 nM	PLK3, IC₅₀: 50.2 nM		99.75%
(Z)-LFM-A13	Plx1, IC₅₀: 10 μM		PLK3, IC₅₀: 61 μM		99.80%
Ocifisertib fumarate				PLK4, IC₅₀: 2.8 nM	99.44%
HMN-214	PLK1				99.16%
TC-S 7005	PLK1, IC₅₀: 214 nM	PLK2, IC₅₀: 4 nM	PLK3, IC₅₀: 24 nM		99.68%
Plogosertib	PLK1, IC₅₀: 3 nM	PLK2, IC₅₀: 149 nM	PLK3, IC₅₀: 393 nM		99.95%
Poloxin	PLK1 PBD, IC₅₀: 4.8 μM	PLK2 PBD, IC₅₀: 18.7 μM	PLK3 PBD, IC₅₀: 53.9 μM		98.01%
SBE13 Hydrochloride	PLK1, IC₅₀: 200 pM		PLK3, IC₅₀: 875 nM		99.66%
(1E)-CFI-400437 dihydrochloride				PLK4, IC₅₀: 0.6 nM	98.08%
Dihydrobaicalein	PLK1				99.94%
PLK4-IN-4				PLK4, IC₅₀: 7.9 nM	99.89%
Cyclapolin 9	PLK1, IC₅₀: 500 nM				99.16%
PLK1/BRD4-IN-5	PLK1, IC₅₀: 0.3 nM				99.55%
PLK1/BRD4-IN-3	PLK1, IC₅₀: 0.127 μM				99.66%
TAK-960 dihydrochloride	PLK1, IC₅₀: 0.8 nM	PLK2, IC₅₀: 16.9 nM	PLK3, IC₅₀: 50.2 nM		99.19%
Poloxime	PLK1
LFM-A13	Plx1, IC₅₀: 10 μM		PLK3, IC₅₀: 61 μM		99.65%
SBE13	PLK1, IC₅₀: 200 pM		PLK3, IC₅₀: 875 nM
Volasertib trihydrochloride	PLK1, IC₅₀: 0.87 nM	PLK2, IC₅₀: 5 nM	PLK3, IC₅₀: 56 nM
(E/Z)-Rigosertib sodium	PLK1
BTO-1	Plx1
PLK1-IN-6	PLK1, IC₅₀: 0.45 nM	PLK2, IC₅₀: 5.73 nM	PLK3, IC₅₀: 7.56 nM
WNY0824	PLK1, IC₅₀: 22 nM
YLT-11	PLK1, Kd: >10000 nM	PLK2, Kd: 653 nM	PLK3, Kd: >10000 nM	PLK4, Kd: 5.2 nM
PLK4-IN-3				PLK4, IC₅₀: ≤ 0.1 μM
CZS-241				PLK4, IC₅₀: 2.6 nM
PLK1-IN-5	PLK1, IC₅₀: <500 nM
PLK1-IN-10	PLK1 PBD
IIP0943	PLK1, IC₅₀: 5.1 nM
TAK-960 hydrochloride	PLK1, IC₅₀: 0.8 nM	PLK2, IC₅₀: 16.9 nM	PLK3, IC₅₀: 50.2 nM
Ocifisertib hydrochloride				PLK4, IC₅₀: 2.8 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Related Products (88)

Recombinant Proteins (2)

Antibodies (3)

Polo-like Kinase (PLK) Isoform Comparison

Polo-like Kinase (PLK) Related Products (88):